| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/23/2023 |
8-K
| Quarterly results |
| 12/16/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/20/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Transition Agreement, by and between the Company and Eric Richman",
"AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement is effective as of , by and between Gain Therapeutics, Inc. and Matthias Alder . This Agreement amends, restates, and supersedes in its entirety the Employment Agreement between the Company and Executive entered into effective October 15, 2021 . WHEREAS, the Company desires to continue to retain the services of Executive, now in the role of Chief Executive Officer as further set forth in this Agreement; WHEREAS, the Company’s Board of Directors desires to appoint Executive as the Company’s President and Chief Executive Officer as further set forth in this Agreement, effective as of the Effective Date; and WHEREAS, Executive desires to serve the Company in such capacity, subject to the terms and conditi...",
"GAIN THERAPEUTICS Announces PROMOTION OF Matthias Alder TO chief executive officer" |
|
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/17/2022 |
8-K
| Quarterly results |
| 06/02/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/23/2022 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 05/13/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/02/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 03/25/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/24/2022 |
8-K
| Quarterly results |
| 12/28/2021 |
8-K
| Quarterly results |
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/12/2021 |
8-K
| Quarterly results |
| 10/20/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 08/11/2021 |
8-K
| Quarterly results |
| 05/10/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 05/10/2021 |
8-K
| Quarterly results |
| 05/04/2021 |
8-K
| Quarterly results |
| 04/06/2021 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/22/2021 |
8-K
| Quarterly results |
| 03/19/2021 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 03/18/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/17/2021 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
|